Literature DB >> 30394352

Targeting cytokines to treat autoinflammatory diseases.

Jonathan S Hausmann1.   

Abstract

Autoinflammatory diseases are rare group of conditions manifested by recurrent fevers, systemic inflammation, and dysfunctions of the innate immune system. These conditions are characterized by overproduction or lack of inhibition of various cytokines, and the advent of biologic drugs that block specific cytokines involved in these conditions has revolutionized their treatment. In this review, I will discuss the most common autoinflammatory conditions of adulthood including familial Mediterranean fever (FMF), cryopyrin-associated periodic syndrome (CAPS), mevalonate kinase deficiency/hyperimmunoglobulinemia D Syndrome (MKD/HIDS), TNF receptor-associated autoinflammatory syndrome (TRAPS), and systemic juvenile idiopathic arthritis/adult-onset Still's disease (SJIA/AOSD). I will discuss how IL-1, IL-6, IL-18, and TNF play pathogenic roles in these conditions and will review the evidence behind cytokine blockade for these diseases. Throughout the paper, I will reflect on gaps in knowledge of autoinflammatory diseases and will highlight the latest advances and newest drugs in development.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adult-onset Still's disease; Autoinflammatory diseases; Biologics; CAPS; Cytokine inhibitors; FMF; HIDS; Interleukin-1; Interleukin-18; Interleukin-6; MKD; TRAPS; Tumor necrosis factor

Mesh:

Substances:

Year:  2018        PMID: 30394352     DOI: 10.1016/j.clim.2018.10.016

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  16 in total

1.  Advances in Disease Mechanisms and Translational Technologies: Clinicopathologic Significance of Inflammasome Activation in Autoimmune Diseases.

Authors:  J Michelle Kahlenberg; Insoo Kang
Journal:  Arthritis Rheumatol       Date:  2020-01-15       Impact factor: 10.995

2.  Clinical characteristics and comorbidities in adult-onset Still's disease using a large US administrative claims database.

Authors:  Aleksander Lenert; GYeon Oh; Michael J Ombrello; Sujin Kim
Journal:  Rheumatology (Oxford)       Date:  2020-07-01       Impact factor: 7.580

Review 3.  Interfering with interferons: targeting the JAK-STAT pathway in complications of systemic juvenile idiopathic arthritis (SJIA).

Authors:  Emely L Verweyen; Grant S Schulert
Journal:  Rheumatology (Oxford)       Date:  2022-03-02       Impact factor: 7.046

Review 4.  Autoimmune and Autoinflammatory Pericarditis: Definitions and New Treatments.

Authors:  Emanuele Bizzi; Lucia Trotta; Massimo Pancrazi; Mariangela Nivuori; Valeria Giosia; Luca Matteucci; Daniela Montori; Antonio Brucato
Journal:  Curr Cardiol Rep       Date:  2021-07-28       Impact factor: 2.931

5.  Distinct Gene Expression Signatures Characterize Strong Clinical Responders Versus Nonresponders to Canakinumab in Children With Systemic Juvenile Idiopathic Arthritis.

Authors:  Emely L Verweyen; Alex Pickering; Alexei A Grom; Grant S Schulert
Journal:  Arthritis Rheumatol       Date:  2021-05-31       Impact factor: 15.483

Review 6.  Update on the management of colchicine resistant Familial Mediterranean Fever (FMF).

Authors:  Georges El Hasbani; Ali Jawad; Imad Uthman
Journal:  Orphanet J Rare Dis       Date:  2019-10-15       Impact factor: 4.123

Review 7.  Systemic autoinflammatory diseases.

Authors:  Julie Krainer; Sandra Siebenhandl; Andreas Weinhäusel
Journal:  J Autoimmun       Date:  2020-02-01       Impact factor: 7.094

8.  Single-Chain Soluble Receptor Fusion Proteins as Versatile Cytokine Inhibitors.

Authors:  Aurora Holgado; Harald Braun; Kenneth Verstraete; Domien Vanneste; Nico Callewaert; Savvas N Savvides; Inna S Afonina; Rudi Beyaert
Journal:  Front Immunol       Date:  2020-07-13       Impact factor: 7.561

9.  Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial.

Authors:  Claudia Kedor; Joachim Listing; Jan Zernicke; Anja Weiß; Frank Behrens; Norbert Blank; Joerg Christoph Henes; Joern Kekow; Andrea Rubbert-Roth; Hendrik Schulze-Koops; Eva Seipelt; Christof Specker; Eugen Feist
Journal:  Ann Rheum Dis       Date:  2020-05-13       Impact factor: 27.973

Review 10.  Monogenic autoinflammatory diseases in adults - a challenge to rheumatologic practice at the onset of the Polish national programme of interleukin 1 inhibitor treatment.

Authors:  Marcin Milchert; Joanna Makowska; Olga Brzezińska; Marek Brzosko; Ewa Więsik-Szewczyk
Journal:  Reumatologia       Date:  2019-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.